Prostate Cancer Lawsuit Filed Over Zantac Heartburn Pills

An Alabama man indicates he was diagnosed with prostate cancer from Zantac, alleging the popular heartburn pills exposed him to high levels of cancer-causing chemicals for years.

The complaint (PDF) was filed by Virgil Beck in the U.S. District Court for the Northern District of Alabama on March 11, indicating that Boehringer Ingelheim, Sanofi, Pfizer, and GlaxoSmithKline distributed name-brand Zantac pills for decades that produced high levels of N-Nitrosodimethylamine (NDMA), which may increase the risk of prostate cancer, stomach cancer, bladder cancer and other issues.

Beck indicates he took the ranitidine-based heartburn pills for about 26 years before his diagnosis, yet the manufacturers failed to warn consumers and the medical providers about the potential Zantac cancer risks.


Did you or a loved one take recalled Zantac?

Side effects of Zantac may increase the risk of cancer, due to chemical impurities found in the heartburn drug.


Zantac (ranitidine) has been a top selling heartburn drug for decades, becoming the first medication to surpass $1 billion in annual sales in 1988, amid aggressive marketing which established it as a safe and effective treatment for acid reflux and heartburn.

NDMA is a chemical byproduct, which is considered a carcinogen. It used to result from making rocket fuel in the early 1900s, but today is only used in laboratory experiments to induce cancer in animal test subjects.

Beck began using Zantac in 1993, taking about 150 mg per day, and used it through 2019. He was diagnosed with prostate cancer in June 2018.

“Based on prevailing scientific evidence, exposure to Zantac (and the attendant NDMA) can cause prostate cancer in humans,” the lawsuit states. “Had any Defendant warned Plaintiff that Zantac could lead to exposure to NDMA or, in turn, cancer, Plaintiff would not have taken Zantac.”

There are more than 3 million cases of prostate cancer diagnosed in the U.S. each year and is one of the most common types of cancer each year. It often grows slowly, and is treatable as long as it is contained to the prostate. Once it metastasizes to other parts of the body, the chances of survival are greatly diminished.

This cases joins dozens of Zantac lawsuits filed in recent weeks that involve former users who indicate they have already been diagnosed with cancer following years of exposure to ranitidine. In addition to bladder cancer, lawsuits allege that plaintiffs have also developed stomach cancer, colorectal cancer, esophageal cancer, liver cancer, kidney cancer and other cancers along the digestive tract.

To deal with the increasing complaints being filed throughout the federal court system, the U.S. Judicial Panel on Multidistrict Litigation recently ordered that all Zantac cases be centralized and consolidated in the U.S. District Court for the Southern District of Florida, where the litigation will be overseen by U.S. District Judge Robin L. Rosenberg during coordinated discovery and pretrial proceedings.


  • ReginaJune 11, 2021 at 3:13 am

    My grandfather passed away and he had prostate cancer and he was taken Ranitidine 150mg

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted 2 days ago)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted 2 days ago)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.